Metagenomi (MGX) Expected to Announce Quarterly Earnings on Tuesday

Metagenomi (NASDAQ:MGX) is anticipated to post its Q1 2025 quarterly earnings results before the market opens on Tuesday, May 13th. Analysts expect Metagenomi to post earnings of ($0.62) per share for the quarter.

Metagenomi (NASDAQ:MGX) last issued its quarterly earnings results on Monday, March 17th. The company reported ($0.63) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.62) by ($0.01). Metagenomi had a negative net margin of 134.27% and a negative return on equity of 43.23%. The business had revenue of $9.61 million during the quarter, compared to analyst estimates of $13.18 million. During the same quarter in the previous year, the firm posted ($20.05) earnings per share. On average, analysts expect Metagenomi to post $-2 EPS for the current fiscal year and $-3 EPS for the next fiscal year.

Metagenomi Trading Down 3.8 %

Shares of Metagenomi stock traded down $0.06 during trading hours on Tuesday, reaching $1.51. 16,170 shares of the company’s stock were exchanged, compared to its average volume of 770,751. Metagenomi has a fifty-two week low of $1.23 and a fifty-two week high of $8.17. The stock has a market cap of $56.45 million, a P/E ratio of -0.58 and a beta of -0.65. The company has a 50 day moving average of $1.66 and a two-hundred day moving average of $2.30.

Institutional Trading of Metagenomi

An institutional investor recently raised its position in Metagenomi stock. Bank of America Corp DE lifted its stake in shares of Metagenomi, Inc. (NASDAQ:MGX) by 482.9% in the 4th quarter, according to its most recent Form 13F filing with the SEC. The institutional investor owned 21,113 shares of the company’s stock after buying an additional 17,491 shares during the period. Bank of America Corp DE owned about 0.06% of Metagenomi worth $76,000 as of its most recent SEC filing.

Wall Street Analyst Weigh In

A number of brokerages have recently issued reports on MGX. HC Wainwright dropped their price objective on Metagenomi from $14.00 to $7.00 and set a “buy” rating on the stock in a research note on Thursday, April 3rd. Wells Fargo & Company decreased their price objective on shares of Metagenomi from $25.00 to $20.00 and set an “overweight” rating for the company in a research report on Tuesday, March 18th.

About Metagenomi

Metagenomi, Inc, a genetic medicines company, develops therapeutics for patients using metagenomics-derived genome editing toolbox in the United States. The company's genome editing toolbox includes programmable nucleases, base editors, and RNA and DNA-mediated integration systems, such as prime editing systems and clustered regularly interspaced short palindromic repeat-associated transposases.